These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10456219)

  • 1. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
    Beghin L; Capps N; Duhal N; Davies J; Staels B; Luc G
    Ann Clin Biochem; 1999 Jul; 36 ( Pt 4)():523-5. PubMed ID: 10456219
    [No Abstract]   [Full Text] [Related]  

  • 2. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 6. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E; Dejager S; Chapman MJ
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
    Legras B; Clerc C; Ruelland A; Doualin G; Fertil V; Cloarec L
    Clin Chem; 1990 Mar; 36(3):580-1. PubMed ID: 2107044
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in hyperlipidaemic patients.
    Branchi A; Rovellini A; Sommariva D
    Int J Clin Pharmacol Res; 1995; 15(4):153-8. PubMed ID: 8871265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of apolipoprotein AI, AII, and E in plasma and lipoprotein fractions of alcoholic patients: gender differences in the effects of alcohol.
    Lin RC; Miller BA; Kelly TJ
    Hepatology; 1995 Apr; 21(4):942-9. PubMed ID: 7705804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC; de Valois JC; van den Ende B; Wouter ten Cate J; Kastelein JJ
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
    Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
    Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
    [No Abstract]   [Full Text] [Related]  

  • 15. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 16. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.
    Turay J; Grniaková V; Valka J
    Drugs Exp Clin Res; 2000; 26(3):83-8. PubMed ID: 10941600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reduction of lipoproteins with apoAI but without apoAII (LpAI) in non-insulin-dependent diabetic patients].
    Barkia A; Zouari N; Khrouf W; Ellouz F; Zouaghi H
    Ann Biol Clin (Paris); 1996; 54(2):83-6. PubMed ID: 8763631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperinsulinemia inhibits secretion of apo AI more efficiently than secretion of apoAII and apoE (insulin and secretion of apoproteins).
    Goldsztajn P; Guzdek A; Kruszelnicka-Kwiatkowska O; Guevara I; Kwaśniak M; Harwich J; Piwowarska W; Dembińska-Kieć
    Z Gastroenterol; 1996 Jun; 34 Suppl 3():46-8. PubMed ID: 8767459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.